María
Díez Campelo
Profesora Asociada CC. Salud
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Central de Asturias (20)
2024
-
Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms
British Journal of Haematology
-
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535
2023
-
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690
-
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
HemaSphere, Vol. 7, Núm. 10, pp. E961
2022
2021
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
2017
-
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Leukemia Research, Vol. 63, pp. 85-89
-
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621
-
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541
-
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597
2016
-
Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes
Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292
-
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes
Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551
2015
-
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Leukemia Research, Vol. 39, Núm. 3, pp. 296-306
-
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients
Leukemia Research, Vol. 38, Núm. 10, pp. 1199-1206
-
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome
Leukemia Research, Vol. 38, Núm. 5, pp. 551-556
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
Leukemia Research, Vol. 38, Núm. 3, pp. 304-309
2013
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177